PIRAMAL PHARMA LIMITED
Piramal Pharma Limited operates as a pharmaceutical company in the United States, Europe, Japan, India, and internationally. The company offers a portfolio of pharmaceutical products and services through global development and manufacturing facilities and distribution network. It also operates contract development and manufacturing organization that provides services across the drug life cycle, including discovery, development, and commercial manufacturing of drug substances and products; offers inhalation anesthetics, intrathecal therapy, injectable pain and anesthesia drugs, and other generic and specialty products; and analgesics, skin care, vitamin/mineral supplement, kids' wellness, digestives, women's health, and hygiene, as well as adult incontinence. The company was incorporated in 2020 and is based in Mumbai, India.
Valuation
Profitability
Returns
Solvency
AI Summary
Indian StockStrengths1
- Revenue grew 20.4% YoY
Concerns1
- Low return on equity of 5.8%
Rule-based from financial data. Not advice.
Monthly Returns
Year-to-Date ROI
Historical Volatility
Historical Performance
Revenue, profitability, and cash flow trends (βΉ Crores)
Revenue (10Y)
Operating Income (10Y)
Net Profit (10Y)
Operating Margin % (10Y)
Dividend Payout % (10Y)
Free Cash Flow (10Y)
Growth Summary
Latest fiscal year: Mar 2025
Historical Growth
Year-by-year revenue, profitability, and cash flow (βΉ Crores, last 5 years)
| Year | Revenue | Op. Income | Net Profit | CFO | FCF | ROE | Rev Growth 1Y | NP Growth 1Y |
|---|---|---|---|---|---|---|---|---|
| Mar 2025 | βΉ5.29 K Cr | β | βΉ691.00 Cr | β | β | 9.3% | 20.4% | 76.7% |
| Mar 2024 | βΉ4.39 K Cr | β | βΉ391.00 Cr | β | β | 5.8% | 27.5% | 458.6% |
| Mar 2023 | βΉ3.44 K Cr | β | βΉ70.00 Cr | β | β | 1.3% | 3.1% | -81.0% |
| Mar 2022 | βΉ3.34 K Cr | β | βΉ368.00 Cr | β | β | 7.2% | 13.6% | -35.7% |
| Mar 2021 | βΉ2.94 K Cr | β | βΉ572.00 Cr | β | β | 13.9% | β | β |
Financial Statements
Income statement, balance sheet, and cash flow (βΉ Crores, as reported)
Consolidated Figures in USD Millions.
| Unnamed: 0 | TTM |
|---|---|
| Revenue / Net Sales | 5,035 |
| Total Expenses | 4,228 |
| EBIT / Operating Profit | 807 |
| OPM % | 16% |
| Other Income | 447 |
| Finance Costs | 103 |
| Depreciation & Amortisation | 237 |
| Profit Before Tax | 914 |
| Tax % | - |
| Net Profit / PAT | 706 |
| EPS (βΉ) | 5.32 |
| Dividend Payout % | - |
Peer Comparison
Healthcare sector peers, ranked by market cap
| Company | Market Cap | Revenue | P/E | P/B | EV/EBITDA | Rev G 1Y |
|---|---|---|---|---|---|---|
| PIRAMAL PHARMA LIMITEDthis co. | βΉ22.36 K Cr | βΉ5.29 K Cr | 31.70 | 2.89 | 27.56 | 20.4% |
| Sun Pharmaceutical Industries Ltd. | βΉ4.15 L Cr | βΉ23.00 K Cr | 88.70 | 17.43 | 72.30 | 13.5% |
| Divi's Laboratories Ltd. | βΉ1.71 L Cr | βΉ9.20 K Cr | 67.90 | 11.13 | 67.21 | 20.0% |
| Torrent Pharmaceuticals Ltd. | βΉ1.33 L Cr | βΉ9.68 K Cr | 62.50 | 15.76 | 45.64 | 13.5% |
| Cipla Ltd. | βΉ1.17 L Cr | βΉ19.05 K Cr | 22.50 | 3.51 | 19.33 | 14.9% |
| Apollo Hospitals Enterprises Ltd. | βΉ1.05 L Cr | βΉ8.20 K Cr | 75.00 | 11.28 | 54.44 | 12.8% |
| Max Healthcare Institute Limited | βΉ1.00 L Cr | βΉ2.66 K Cr | 144.00 | 11.76 | 96.84 | 13.8% |
| Industry Average | β | βΉ3.29 K Cr | 98.63 | 8.11 | 65.50 | 20.2% |